Alimera sciences announces national pricing and reimbursement granted for iluvien® for dme in belgium

Atlanta, aug. 24, 2021 (globe newswire) -- alimera sciences, inc. (nasdaq: alim) (alimera), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, announces that alimera sciences europe limited, its ireland-based european subsidiary, received pricing and reimbursement approval for iluvien® for diabetic macular edema (dme) in belgium from the national institute for health and disability insurance (inami). pricing and reimbursement approval was sought and secured by alimera's distribution partner in france and the benelux region, horus pharma s.a.s. (horus). horus is currently in the launch phase in belgium.
ALIM Ratings Summary
ALIM Quant Ranking